TRCT
WHWK

Tower Research Capital (TRC)’s Whitehawk Therapeutics WHWK Stock Holding History

Tower Research Capital (TRC)’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.7K Buy
+2,555
New +$10.6K ﹤0.01% 3935
2025
Q4 		– Sell
-797
Closed -$1.51K – 5750
2025
Q3 		$1.51K Sell
797
-3,301
-81% -$6.07K ﹤0.01% 4774
2025
Q2 		$7.66K Buy
4,098
+1,543
+60% +$2.69K ﹤0.01% 4044
2025
Q1 		$4.55K Buy
2,555
+2,141
+517% +$5.59K ﹤0.01% 4240
2024
Q4 		$1.31K Sell
414
-1,379
-77% -$3.12K ﹤0.01% 5049
2024
Q3 		$3.69K Sell
1,793
-11,875
-87% -$19.2K ﹤0.01% 4795
2024
Q2 		$20K Buy
13,668
+10,169
+291% +$18.8K ﹤0.01% 3766
2024
Q1 		$8.19K Sell
3,499
-1,772
-34% -$3.42K ﹤0.01% 4065
2023
Q4 		$10.6K Sell
5,271
-11,330
-68% -$47.5K ﹤0.01% 4220
2023
Q3 		$80.3K Buy
16,601
+15,081
+992% +$87.7K ﹤0.01% 2148
2023
Q2 		$10.4K Buy
1,520
+392
+35% +$3.05K ﹤0.01% 4127
2023
Q1 		$8K Sell
1,128
-3,488
-76% -$37.3K ﹤0.01% 4683
2022
Q4 		$60K Sell
4,616
-1,846
-29% -$24.1K ﹤0.01% 2214
2022
Q3 		$91K Buy
6,462
+2,408
+59% +$31.6K ﹤0.01% 2648
2022
Q2 		$50K Buy
4,054
+2,607
+180% +$38.7K ﹤0.01% 2887
2022
Q1 		$25K Buy
1,447
+1,277
+751% +$24.5K ﹤0.01% 3341
2021
Q4 		$4K Buy
170
+130
+325% +$3.27K ﹤0.01% 5355
2021
Q3 		$1K Buy
+40
New +$1.22K ﹤0.01% 5557
2021
Q2 		– Sell
-219
Closed -$4K – 5919
2021
Q1 		$4K Sell
219
-8
-4% -$184 ﹤0.01% 4819
2020
Q4 		$3K Buy
227
+46
+25% +$984 ﹤0.01% 4837
2020
Q3 		$4K Sell
181
-833
-82% -$17.5K ﹤0.01% 4449
2020
Q2 		$19K Buy
+1,014
New +$13.3K ﹤0.01% 3714
2019
Q1 		– Sell
-274
Closed -$7K – 4365
2018
Q4 		$7K Buy
+274
New +$8.72K ﹤0.01% 2727
2018
Q3 		– Sell
-7
Closed – – 4320
2018
Q2 		$0 Buy
+7
New +$423 ﹤0.01% 4135

Other funds holding WHWK

YF
Yu Fan $108M AUM 137.54% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $136M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tower Research Capital (TRC)'s WHWK Position: Q2 2026 in Review

Tower Research Capital (TRC) opened a new position in Whitehawk Therapeutics (WHWK) in Q2 2026: 2,555 shares worth $11.7K. The stake represents ﹤0.01% of the portfolio and ranks #3935 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in WHWK as recently as Q3 2025.

Tower Research Capital (TRC) first reported a position in WHWK in Q2 2018 and has held it in 24 quarters since. The position peaked at $91K in Q3 2022. 77 funds tracked by Wall St. Rank hold WHWK as of Q2 2026.

  • Tower Research Capital (TRC) held 2,555 shares of Whitehawk Therapeutics worth $11.7K as of Q2 2026.
  • Whitehawk Therapeutics was a new Tower Research Capital (TRC) position in Q2 2026.
  • Whitehawk Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3935 holding.
  • Tower Research Capital (TRC) first reported a position in Whitehawk Therapeutics in Q2 2018 and has held it in 24 quarters since.
  • Tower Research Capital (TRC)'s Whitehawk Therapeutics position peaked at $91K in Q3 2022.
  • 77 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.